Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
about
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infectionImproved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170Practical methods for competing risks data: a review.Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa.Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in careTreatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factorsCorrelates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia.Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in CanadaCD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption.Impact of and Correction for Outcome Misclassification in Cumulative Incidence Estimation.Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHODComparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort.Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infectionAntiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.Risk factors for unstructured treatment interruptions and association with survival in low to middle income countriesAntiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy.HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical modelTaking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existing and upcoming challenges.Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review.Socioeconomic and clinical factors explaining the risk of unstructured antiretroviral therapy interruptions among Kenyan adult patients.Sex-specific differences in treatment outcomes for patients with HIV and AIDS.Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center.Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women
P2860
Q28478848-3A464585-E7A8-49CB-B463-51DBB9B5690EQ33377920-A9DE8BE5-1A38-42F4-860C-BA6C19F3E955Q33788920-72000847-81FC-4CCF-A0D1-0DF63116EB92Q33999150-7017B109-6157-43AE-A518-2B80BB323B10Q34148055-4D28EE59-554C-4B64-AE5B-DF6D811A1D7FQ34427862-2F919990-25F1-4A02-97A9-340626464D85Q34508220-67D2B7BD-1143-4464-BADB-0B278497758AQ34756298-A5E2E70C-FB13-4121-9077-5AE0916AF2F7Q34989696-22275029-4A36-4142-8037-7267C5DEF2B7Q35166919-70818EE9-9F55-420A-9DE9-6909DCF5041EQ35762036-C4E0675E-4C9F-477A-B477-A66D697A5B1FQ35948083-CE484B03-C2E7-460D-AFC6-3D21F1709909Q36275359-4D9D930F-351F-4516-B5CC-4543D1E569F5Q36408171-151C6AD1-FE43-4DD8-ADF4-708CC70BDB58Q36544183-3768CD4B-F135-4225-8F5B-DCC67942C6CCQ36875697-FE5B6A93-0779-4CF4-9701-C5F9B854407FQ37085020-413042F7-8DC7-44AE-8110-EB16D1511BB7Q37404322-F6FE7228-525B-4C1A-A8B4-DE249FB6E813Q37483779-C7B86E7E-3680-4507-9123-2C7F667F49E5Q37531241-900CCC55-E115-40E8-A4AB-AD1DB7AA06B6Q37896165-8130F904-C79A-46AC-AF0C-16CC4FBB24C1Q40023160-948D40C7-B638-45FB-9784-BE85FEAB1269Q40129396-49913474-D19F-463C-8B6E-31EAD842609CQ40477509-E1EF4DF4-89BA-4498-9EEB-6603AD9787D6Q42256493-9065FD07-B547-4D34-AA74-7AA864A96764Q57757288-206376F0-7FAF-4E6B-9023-089C29A46AE1
P2860
Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Highly active antiretroviral t ...... and immunologic consequences.
@en
Highly active antiretroviral t ...... and immunologic consequences.
@nl
type
label
Highly active antiretroviral t ...... and immunologic consequences.
@en
Highly active antiretroviral t ...... and immunologic consequences.
@nl
prefLabel
Highly active antiretroviral t ...... and immunologic consequences.
@en
Highly active antiretroviral t ...... and immunologic consequences.
@nl
P2093
P1476
Highly active antiretroviral t ...... l and immunologic consequences
@en
P2093
Anna Antoniou
CASCADE Collaboration
Giota Touloumi
Heide A Stirnadel
Nikos Pantazis
Sarah A Walker
P304
P356
10.1097/01.QAI.0000230321.85911.DB
P407
P577
2006-08-01T00:00:00Z